Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission ...

Dosing has started in a clinical evaluating peluntamig, which targets DLL3 and CD47, combined with chemotherapy in patients ...

In October 2024, Crescent entered into an acquisition agreement with Rockville, Maryland-based GlycoMimetics, Inc. (NASDAQ: ...

Q4 net sales of $84.1 million and $310.0 million for full year 2024; continued growth expected in 2025Executing on ...

Zymeworks (ZYME) announced achievement of a $14M cash research milestone from GSK (GSK) associated with a clinical milestone. “In April 2016, ...

Zymeworks Inc. (Nasdaq: ZYME) a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics ...

Clinical validation of the Azymetric platform is demonstrated by the accelerated approval of Ziihera® (zanidatamab-hrii), a ...

Genmab A/S (Nasdaq: GMAB) will increase its share capital by 10,058 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the ...

The leading Advanced Merkel Cell Carcinoma Companies such as Xencor, Inc., Incyte Corporation, Millennium Pharmaceuticals, ...

The general mood among these heavyweight investors is divided, with 62% leaning bullish and 18% bearish. Among these notable ...

The trial will test four dose levels and include up to 18 patients with advanced, FLT3-expressing acute myeloid leukemia.

National Biotechnology Conference, gene therapies, bispecific antibodies and other novel modalities—relative newcomers to ...